CBS 11 Header TXA 21 Header MeTV Header KRLD Header The Fan Header
CBS DFW WEATHER APP: iPhone App Store | Android App Coming Soon | More Information

News

FDA Approves Meningitis Vaccine For Infants

View Comments

CBS DFW (con't)

Affordable Care Act Updates: CBSDFW.com/ACA

Health News & Information: CBSDFW.com/Health

Get Breaking News First

Receive News, Politics, and Entertainment Headlines Each Morning.
Sign Up

From Our CBS Music Web Sites

454116976 FDA Approves Meningitis Vaccine For InfantsKe$sha's Scandalous Pre-VMA Selfie

452359772 10 FDA Approves Meningitis Vaccine For InfantsBikini Model Pictures

 alt=New Survivor Cast Photos

453947324 FDA Approves Meningitis Vaccine For InfantsIce Bucket Challenge Fail

 alt=Musicians Then And Now

cowb thumb FDA Approves Meningitis Vaccine For InfantsCowboys Cheerleaders

NEW YORK (CBS NEWS) - A new combination vaccine that protects infants from two deadly infections that can cause meningitis, meningococcal disease and Hib disease, was approved Thursday by the U.S. Food and Drug Administration.

The vaccine, called Menhibrix, has been approved for children ages 6 weeks through 18 months old. It’s given as a four-dose series at 2, 4, 6 and 12 through 15 months of age, and the first dose may be given as early as 6 weeks of age. It is manufactured by GlaxoSmithKline.

Meningococcal disease is caused by the bacteria Neisseria meningitides, and is most commonly diagnosed among infants, adolescents and young adults. A common outcome of the infection is meningitis, a life-threatening infection of the covering that surrounds the brain and spinal cord. About 1,000 causes of meningococcal disease occur each year.

The bacteria spreads through respiratory and throat secretions like spit, but aren’t as contagious as the common cold or flu. Infants with meningococcal meningitis may appear to be slow or inactive, irritable, vomiting or feeding poorly, according to the Centers for Disease Control and Prevention.

Click Here To Read More From CBS News

Also Check Out:

View Comments